Partnership Potential Pace Diagnostics' focus on point-of-care diagnostics and its lead programs in tuberculosis and early lung cancer create collaboration opportunities with hospitals, TB programs, and oncology centers for co development, validation, and market entry partnerships.

Licensing Opportunities A small team with a high throughput platform and biomarker portfolio makes licensing, co development, or OEM manufacturing attractive to larger diagnostic players seeking to accelerate scale and market entry.

Regulatory Readiness Leverage existing government grants and contracts to position Pace for regulatory strategy, clinical validation, and reimbursement planning to speed approvals and adoption.

Market Alignment TB and lung cancer POCT programs align with current health trends and screening needs, creating demand for scalable manufacturing, distribution networks, and turnkey lab services.

Growth Capital With revenue in the early to mid range, Pace can pursue strategic investors, SBIR grants, and partnering with larger labs to expand capacity, geographic reach, and recurring revenue.